Hot Features
Elixir Pharmaceuticals, Inc. went out of business. Elixir Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes pharmaceuticals for the treatment of metabolic diseases. It develops small molecule drugs that mimic longevity responses, as well as used to treat a rang... Elixir Pharmaceuticals, Inc. went out of business. Elixir Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes pharmaceuticals for the treatment of metabolic diseases. It develops small molecule drugs that mimic longevity responses, as well as used to treat a range of age-related diseases, including diabetes and obesity. The company’s products include Metgluna and Glinsuna for the treatment of type 2 diabetes; Ghrelin, an oral antagonist for the treatment of metabolic diseases; and EX-1314, an oral drug developed for the treatment of type 1 diabetic gastroparesis. It has strategic alliances/partnerships with Kissei Pharmaceuticals, Bristol-Myers Squibb, Siena Biotech S.p.A., and Novartis Pharmaceuticals. The company was founded in 1999 and is headquartered in Cambridge, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.